Abstract 2039P
Background
Reliable and validated primary endpoints, such as overall survival (OS), are commonly used in oncologic confirmatory randomized controlled trials (RCTs). However, recent studies suggest that these endpoints may not sufficiently measure the true benefits of therapies in older patients with cancer. We conducted a scoping review of the literature to identify primary endpoints used in geriatric oncology RCTs.
Methods
We searched the literature on confirmatory RCTs specific to older patients with cancer using PubMed (National Center for Biotechnology Information) and CINAHL (EBSCO). Studies fulfilling the selection criteria were reviewed according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews, and definitions of primary endpoints were extracted.
Results
A total of 68 RCTs met the inclusion criteria. Data on geriatric assessment and quality of life (QOL) were extracted in 66 (97.1%) and 25 (36.8%) RCTs, respectively. Fifty-two RCTs (76.5%) used traditional outcomes, such as OS, DFS, relapse-free survival, progression-free survival, and response rate, as primary endpoints; however, one RCT used OS adjusted for QOL as a primary endpoint and one RCT used OS and health-related QOL as a combination primary endpoint. Three of the four RCTs using time-to-event endpoint as the primary endpoint included toxic effect as an event in addition to disease progression and death due to any cause. Toxic effect was a primary outcome measure in six RCTs (8.8%) which utilized the National Cancer Institute Common Terminology Criteria for Adverse Events. Health-related QOL, including the EORTC QOL Questionnaire core version 30 items, was a primary endpoint in three RCTs (4.4%). Barthel index for activities of daily living and the confusion assessment method for delirium were used in two RCTs (2.9%).
Conclusions
Although most geriatric oncology RCTs used traditional primary endpoints, some RCTs utilized innovative primary endpoints to more appropriately measure treatment benefit for older patients with cancer. This scoping review should be helpful for methodological discussions among investigators and efficient use of these endpoints.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2116P - Preoperative body mass index, waist circumference, and mortality after major cancer surgery: A nationwide cohort study in South Korea
Presenter: Jiwon Yoon
Session: Poster session 06
2117P - Dietary patterns and clinical outcomes in patients with lung cancer: What needs to change
Presenter: Imanuely Borchardt
Session: Poster session 06
2118P - Refeeding syndrome: A prospective analysis in adults admitted to an oncology hospital
Presenter: Filipe Gonçalves
Session: Poster session 06
2119P - The prognostic impact of nutritional assessment and scores in advanced gastric cancer
Presenter: Sara Torresan
Session: Poster session 06
2120P - Nutritional deficiency post gastric cancer surgery
Presenter: Abay Makishev
Session: Poster session 06
2121P - Association between nutritional status and adverse events in gastrointestinal cancer patients undergoing outpatient chemotherapy in Japan
Presenter: Naoko Sato
Session: Poster session 06
2122P - Clinical significance of oncology patients’ nutritional status assessment
Presenter: Efthymios Kostaridis
Session: Poster session 06
2123P - Value of immuno-nutritional scores in the prognosis of hospitalised patients with lung cancer
Presenter: Jesús López
Session: Poster session 06
2124P - The impact of NUTRItional status at first medical oncology visit ON Clinical Outcomes: The NUTRIONCO study
Presenter: Maurizio Muscaritoli
Session: Poster session 06
2125P - Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study
Presenter: Alessio Cortellini
Session: Poster session 06